Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Crohn's disease epidemiology and demographics

Introduction

Overview

Overview

Crohn’s disease (CD) affects more than 1 million people in the United States and more than 3 million worldwide.[1] CD is no longer confined to high-income Western populations. In early-industrialized regions (North America, Europe, Oceania), adult incidence has plateaued or declined, while prevalence keeps rising (“compounding prevalence”). The steepest incidence increases are now in newly industrialized regions of Asia, Latin America, and Africa.[2][3] Peak age at diagnosis is roughly 15–35 years, with a smaller later peak. Pediatric and very-early-onset disease continue to rise even where adult incidence has stabilized.[4] There is no consistent sex predominance in adults. Prevalence in the United States is highest in White Americans, but CD occurs in all racial and ethnic groups.[5]

Epidemiology and Demographics

Epidemiology and Demographics

Burden of disease

  • U.S. administrative-claims data estimate a standardized CD prevalence of 305 per 100,000 population (about 1.01 million Americans).[5]
  • Total inflammatory bowel disease (IBD) prevalence in the same data is 721 per 100,000 (about 2.39 million Americans).[5]
  • Across North America, Oceania, and much of Europe, IBD prevalence exceeds 0.3%.[2]

Incidence

  • Incidence varies widely by region. Contemporary population-based estimates are summarized below.
Region Reported CD incidence / trend Source
North America ~6.3–23.8 per 100,000 person-years; highest adult rates in Canada (~23.8) and the United States (~13.9) [6][4]
Europe ~0.3–12.7 per 100,000 person-years; Denmark rose from 9.1 (1995) to 17.8 (2016) per 100,000 person-years [2][4]
Oceania Among the highest reported (Australia ~29.3 per 100,000 person-years) [2]
Latin America Rising rapidly; Brazil annual percentage change ~+11.1% (1988–2012) [2]
Asia Historically low, now rising; Taiwan annual percentage change ~+4.0% (1998–2008) [2]
Africa Sparse data; available data suggest rising incidence; South African estimates (~3 per 100,000) resemble Asian rather than Western rates [7]

Prevalence

  • The highest reported prevalence is in Europe (up to 322 per 100,000, Germany) and Canada (~319 per 100,000).[2]
  • Prevalence remains low but is increasing in newly industrialized countries.[2][3]
  • IBD evolves through four epidemiologic stages:[3]
    1. Emergence: low incidence and low prevalence.
    2. Acceleration in incidence: rapidly rising incidence with low prevalence. This is the current stage for much of Asia, Latin America, and Africa.
    3. Compounding prevalence: incidence decelerates, plateaus, or declines while prevalence climbs steadily. This is the current stage for North America, Western Europe, and Oceania.
    4. Prevalence equilibrium: prevalence plateaus as an aging patient population reaches a demographic balance. This stage is modeled but not yet observed.
  • Compounding prevalence reflects the accumulation of chronic cases, low disease-specific mortality, and aging of the IBD population. It does not necessarily mean more new disease.[3]
  • The rise in newly industrialized regions is attributed to urbanization, Westernized diet, and industrialization.[3][8]

Geography

  • A north–south gradient and an urban–rural gradient persist within and between countries.[8][9]
  • In sub-Saharan Africa, true incidence and prevalence are uncertain. Contributing factors include limited endoscopic, histopathologic, and imaging capacity, and misattribution to infections that mimic IBD (e.g., intestinal tuberculosis).[10] Low reported rates should not be read as a true low burden.
Demographics

Demographics

Age

  • Peak age at diagnosis is ~15–35 years, with a smaller second peak at ~50–60 years.[6]
  • Whether the distribution is truly bimodal is debated. U.S. claims data show IBD incidence peaking in the third decade of life, then holding relatively stable from the fourth to eighth decades rather than forming a distinct second peak.[5]
  • Pediatric and very-early-onset CD incidence continues to rise even where adult incidence has plateaued.[4]

Sex

  • There is no consistent sex predominance in adult CD.[4]
  • Regional patterns differ. A slight female predominance is reported in parts of North America and New Zealand, and a male predominance in parts of East Asia (Japan, Korea).[4][11] The reasons are not fully explained.

Race and ethnicity

  • U.S. IBD prevalence per 100,000 population is:[5]
    • White: 812
    • Black: 504
    • Hispanic: 458
    • Asian: 403
  • A historically higher risk in Ashkenazi Jewish populations persists but varies geographically, which implicates both genetic and environmental factors.[8]
  • CD occurs across all racial and ethnic groups. The legacy framing of CD as predominantly a disease of White and European Jewish populations is outdated.[5][2]

Family aggregation and migration

  • Having an affected first-degree relative is the strongest known risk factor (incidence rate ratio ~7.77; 95% CI 7.05–8.56).[4]
  • Monozygotic twin concordance is incomplete, which indicates a substantial environmental contribution.[4]
  • Immigrants who move from low- to high-incidence regions acquire increased risk, especially when they migrate at a younger age. This supports early-life environmental programming.[12]
  • Modifiable environmental associations are covered in risk factors. These include smoking, which increases CD risk in contrast to its protective association in ulcerative colitis, as well as antibiotic exposure, ultra-processed food intake, and physical activity.[6][4]
References

References

  1. ↑ Scott FI; et al. (2025). “AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease”. Gastroenterology. 169 (7): 1397–1448. doi:10.1053/j.gastro.2025.09.038. PMID 41274746 Check |pmid= value (help).
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG (2017). “Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies”. Lancet. 390 (10114): 2769–2778. doi:10.1016/S0140-6736(17)32448-0. PMID 29050646.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S; et al. (2025). “Global evolution of inflammatory bowel disease across epidemiologic stages”. Nature. 642 (8067): 458–466. doi:10.1038/s41586-025-08940-0. PMID 40307548 Check |pmid= value (help).
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Dolinger M, Torres J, Vermeire S (2024). “Crohn’s disease”. Lancet. 403 (10432): 1177–1191. PMID 38437854 Check |pmid= value (help).
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K, Yang JY, Schaubel DE, Hurtado-Lorenzo A, Kappelman MD (2023). “Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States”. Gastroenterology. 165 (5): 1197–1205.e2. doi:10.1053/j.gastro.2023.07.003. PMID 37481117 Check |pmid= value (help).
  6. ↑ 6.0 6.1 6.2 Cushing K, Higgins PDR (2021). “Management of Crohn disease: a review”. JAMA. 325 (1): 69–80. doi:10.1001/jama.2020.18936. PMID 33399844 Check |pmid= value (help).
  7. ↑ Omede M, Itam-Eyo A, Park A, Ikobah J, Ibrahim MK, Chukwudike E, Ali-Ibrahim A, Lydston M, Asombang AW, Ananthakrishnan AN (2026). “Epidemiology, natural history, and treatment of inflammatory bowel disease in Africa: a scoping review”. Clin Gastroenterol Hepatol. 24: 41–56.
  8. ↑ 8.0 8.1 8.2 Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S (2020). “Crohn’s disease”. Nat Rev Dis Primers. 6 (1): 22. doi:10.1038/s41572-020-0156-2. PMID 32242028 Check |pmid= value (help).
  9. ↑ Shivananda S, Lennard-Jones J, Logan R; et al. (1996). “Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)”. Gut. 39 (5): 690–697. PMID 9014768.
  10. ↑ Watermeyer G, Katsidzira L, Setshedi M; et al. (2022). “Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis”. Lancet Gastroenterol Hepatol. 7 (10): 952–961. doi:10.1016/S2468-1253(22)00047-4.
  11. ↑ Ha F, Khalil H (2015). “Crohn’s disease: a clinical update”. Therap Adv Gastroenterol. 8 (6): 352–359. doi:10.1177/1756283X15592585. PMID 26557891.
  12. ↑ Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017). “Crohn’s disease”. Lancet. 389 (10080): 1741–1755. doi:10.1016/S0140-6736(16)31711-1. PMID 27914655.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Aditya Ganti M.B.B.S. [3]